ZVRA · XBRL financial data

Zevra Therapeutics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ZVRA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of revenue	—	2,059	343	2,945	—	—
Research and development	8,843	10,161	—	—	—	—
Selling, general and administrative	—	—	15,038	34,314	54,868	77,616
General and administrative	7,921	8,701	15,343	—	—	—
Operating income (loss)	(5,609)	7,729	(42,505)	(49,604)	(87,003)	(62,943)
Interest expense	4,785	226	335	1,501	7,351	7,977
Income tax expense (benefit)	(34)	34	(786)	0	15,371	3,449
Net income (loss)	(12,760)	(8,555)	(41,543)	(46,049)	(105,511)	83,229
Earnings per share, basic USD per share	(3.21)	(2.11)	(1.20)	(1.30)	(2.28)	1.40
Earnings per share, diluted USD per share	(3.21)	(2.11)	—	—	(2.28)	1.35
Weighted average shares, basic thousands of shares	3,981	29,766	34,489	35,452	46,251	55,311
Weighted average shares, diluted thousands of shares	3,981	29,766	—	—	46,251	57,263

Fiscal years (ZVRA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	4,213	112,346	65,466	43,049	33,785	62,406
Short-term investments	—	0	—	—	—	—
Marketable securities	—	0	16,900	24,688	35,711	128,605
Marketable securities, non-current	—	14,932	0	0	6,010	47,879
Accounts receivable	2,442	1,421	7,185	16,119	10,176	—
Inventory	—	—	671	9,841	1,970	1,740
Prepaid and other current assets	1,481	1,182	1,877	1,824	4,052	6,998
Total current assets	8,382	115,056	93,023	86,938	86,027	223,007
Property and equipment, net	1,039	884	794	736	356	489
Right-of-use asset	1,350	1,141	988	790	657	1,212
Goodwill	—	—	0	4,701	4,701	4,701
Total assets	11,209	132,941	115,529	172,327	178,127	284,731
Accounts payable	1,174	516	3,611	13,987	13,075	2,478
Accrued liabilities	700	700	0	—	—	—
Total current liabilities	7,536	4,230	11,726	73,720	34,065	39,277
Long-term debt	—	—	—	5,066	59,504	61,928
Lease liability, non-current	1,587	1,232	843	456	372	859
Total liabilities	77,621	5,823	29,722	110,463	138,461	130,074
Accumulated deficit	(258,474)	(267,029)	(308,572)	(399,778)	(505,289)	(422,060)
Total stockholders' equity	(66,412)	127,118	85,807	61,864	39,666	154,657
Total liabilities and equity	11,209	132,941	115,529	172,327	178,127	284,731
Common shares outstanding (cover page) thousands of shares	28,376	34,423	34,540	43,426	54,116	58,712

Fiscal years (ZVRA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(12,760)	(8,555)	(41,543)	(46,049)	(105,511)	83,229
Stock-based compensation	2,491	2,436	4,294	5,954	14,906	12,634
Depreciation and amortization	273	257	944	1,006	6,389	4,054
Net cash from operating activities	(1,939)	10,439	(18,717)	(33,535)	(69,665)	(1,598)
Purchases of property and equipment	33	102	93	296	0	835
Net cash from investing activities	(33)	(15,524)	(36,719)	(17,390)	(22,161)	18,127
Proceeds from issuing common stock	—	—	0	6,106	64,516	0
Share repurchases	0	2,814	4,723	3,447	0	—
Proceeds from long-term debt	781	0	—	—	—	—
Net cash from financing activities	2,739	113,109	8,352	28,464	82,108	12,064
Net change in cash	767	108,024	(46,880)	(22,417)	(9,264)	28,621

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Zevra Therapeutics	122,148	37,756	10,047*	59.5M	—	Q3 FY26 10-QSep 30, 2026
Theravance Biopharma	219,766	20,731	(6,965)*	51.9M	55.7 quarters	Q2 FY26 10-QJun 30, 2026
aTYR PHARMA	16,160	not reported	(9,351)*	98.1M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Arvinas	88,000	500	(10,400)*	65.5M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
Arbutus Biopharma	19,171	1,014	(6,018)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
Myriad Genetics	115,200	190,700	(8,300)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
CytoDyn	16,359	not reported	(7,726)	1.5B	2.1 quarters	Q1 FY27 10-QAug 31, 2026
Kura Oncology	70,242	20,874	(62,549)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	213,768	40,863	(14,455)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 1:03 AM ET. The filing on SEC.gov is the record.